Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2013

Jun 6, 2013

151_ip_2013-06-06_4c2926df-8769-426e-a74f-711766884516.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Innovation Efficiency – Evotec Company Overv iew

Evotec AG, Company presentation, Jefferies 2013 Global Healthcare ConferenceJune 3-6, 2013, New York City

Forward-looking s statements

Information set forth in this presen forward-looking statements, whi number of risks and uncertainties. looking statements contained herein judgement of Evotec as of the presentation. Such forward-looki are neither promises nor guaran subject to a variety of risks and many of which are beyond our cont tation containsich involve aThe forward. forwardn represent the date of thising statements ntees, but are d uncertainties trol, and which

could cause actual results to differ materially from those contemplated in these forward looking statements We expressly disclaim any statements.obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on uncertainties, which any such statement is based based.

Agenda

• Evotec at a glance

  • Driving Innovation Efficiency
  • Financial strategy & Outlook

First-in-class and best-in-class drug discovery

Evotec overview 1)

U
i
t
k
d
n
q
u
e
r
a
c
r
e
c
o
r
f
t
a
e
r
1
5
h
i
t
>
y
e
a
r
s
s
o
r
y
,
1
0
0
l
d
i
>
e
a
s
e
r
e
s
,
,
3
0
l
i
i
l
>
p
r
e
-c
n
c
a
d
i
d
t
c
a
n
a
e
s
,
2
0
l
i
i
l
>
c
n
c
a
d
c
o
m
p
o
u
n
s		 S
t
t
i
b
i
d
y
s
e
m
a
c
u
n
a
s
e
,
d
h
i
a
n
c
o
m
p
r
e
e
n
s
v
e
f
i
t
i
i
n
n
o
v
a
o
n
n
r
a
-
t
t
t
d
s
r
u
c
u
r
e
s
o
r
e
u
c
e
t
d
l
t
c
o
s
s
a
n
a
c
c
e
e
r
a
e
d
d
i
r
u
g
s
c
o
v
e
r
y
p
r
o
c
e
s
s		 R
i
h
d
t
i
l
i
c
p
r
o
u
c
p
p
e
n
e
i
l
d
i
P
h
I
I
I,
n
c
u
n
g
a
s
e
P
h
I
I,
P
h
I,
a
s
e
a
s
e
l
i
i
l
d
p
p
r
e
-c
n
c
a
a
n
f
t
d
i
t-
i
u
n
p
a
r
n
e
r
e
r
s
n

l
t
t
c
a
s
s
a
r
g
e
s		 f
f
f
P
i
t
b
l
t
t
r
o
a
e
a
a
s
s
,
i
l
i
t
d
g
r
o
w
n
g
q
u
a
y
a
n
i
t
i
l
d
i
t
h
n
n
o
v
a
o
n
e
a
e
r
w
t
h
i
t
i
s
r
o
n
g
g
c
a
s
p
p
o
s
o
n
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A global company y with a complete offering

Evotec worldwide operatio ons

Sales representation (Boston, Tokyo) Operations & sales representation

1) Manfred Eigen (*1927), German biophysical chemist and work on a special measuring method of fast chemical react d one of the worldwide leading pioneers in biotechnology. In 1967, he won the Nobel Prize in Chemistry for his ions, which, until then, were considered to be immeasurable. He initiated the foundation of Evotec AG.

Drug discovery ou utsourcing is a growth market

Key factors underpinning market dynamics

Agenda

  • Evotec at a glance
  • Driving Innovation Efficiency
  • Financial strategy & Outlook

Addressing the innovation challenge

Innovation Efficiency

Broad stand-alonee execution business

Comprehensive drug disco overy platform – "EVO Apps"

Growth driven by q quality

EVT Execute strategy

Expand offering for xpand customer solutions 1 more complete

Expand footprint wit closer to our custom 2 th services even mers, e.g. US East Coast

Further improve gro 3 profitability oss margins and

Systematic, unbiased
and comprehensive approach

"EVT Integrate & Innovate" disease focus

  • Driving existing product candidates to expand "Pharma pipeline without risk"
  • Offering whole infrastructure and discovery solutions
  • Disease and target track record leveraged across indications

Sig pg nificant progre in the next 24 monss expected nths

Clinical-stage pipeline

C
D
d
i
d
t
r
u
g
a
n
a
e		 (
S
f
)
P
t
t
t
t
h
i
a
r
n
e
r
a
r
o
p
a
r
n
e
r
s
p		 C
P
D		 P
h
I
a
s
e		 P
h
I
I
a
s
e		 P
h
I
I
I
a
s
e		 S
t
t
a
u
s
®
®
D
D
i
i
P
P
2
2
7
7
7
7
a
e
p
(
D
i
b
t
)
a
e
e
s		 T
/
A
d
d
(
2
0
0
7
)
e
a
n
r
o
m
e
a
v		 d
n
2
P
h
I
I
I
i
t
t
a
s
e
r
e
c
r
m
e
n
u
l
d
l
t
t
d
d
c
o
s
e
r
e
s
s
e
p
e
c
e
e
n
u
x
,
f
2
0
1
4
(
)
o
e
E
V
T
3
0
2
(
's
A
l
h
i
e
m
e
r
z
d
i
)
s
e
a
s
e		 (
(
)
)
R
h
2
0
1
1
o
c
e		 S
f
t
t
P
h
I
I,
l
t
a
r
o
a
s
e
r
e
s
u
s
(
)
t
d
2
0
1
5
e
p
e
c
e
e
x
E
V
T
1
0
0
i
s
e
r
e
s
(
)
D
i
e
p
r
e
s
s
o
n		 J
(
2
0
1
2
)
a
n
s
s
e
n		 P
d
i
D
2
0
1
2
t
a
r
n
e
r
e
n
e
c
,
f
P
h
I
I
d
i
t
t
s
a
r
o
a
s
e
u
r
n
g
/
(
)
2
0
1
3
2
0
1
4
e
E
V
T
2
0
1
(
I
i
)
n
s
o
m
n
a		 J
i
X
i
(
2
0
1
0
)
n
g
n		 I
A
i
l
2
0
1
3,
l
n
p
r
a
p
p
r
o
v
a
i
d
f
C
D
E
t
r
e
c
e
v
e
r
o
m
o
l
i
i
l
t
i
l
c
o
m
m
e
n
c
e
c
n
c
a
r
a
s
S
i
i
t
o
m
a
o
p
r
m
(
A
l
)
c
r
o
m
e
g
a
y
…		 A
i
(
2
0
1
2
)
s
p
r
e
o		 P
i
t
a
r
n
e
r
n
g
E
V
T
4
0
1
(
I
f
l
i
)
t
n
a
m
m
a
o
n		 C
b
(
2
0
1
2
)
o
n
a		 P
h
I
I
i
C
h
i
t
t
a
s
e
s
a
r
n
n
a
V
i
a
r
o
u
s		 V
i
a
r
o
u
s		 C
l
i
i
l
t
t
n
c
a
s
a
r
s

Broad first-in-class diabetes product pipeline

Diabetes pipeline overview w

(
)
M
l
l
o
e
c
u
e
s		 I
d
i
t
i
n
c
a
o
n
(
)
h
i
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
u
s		 N
t
e
x
i
l
t
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
®
D
i
P
2
7
7
a
e
p		 1
T
d
i
b
t
y
p
e
a
e
e
s
(
i
d
l
i
)
t
m
m
u
n
o
m
o
u
a
o
n		 d
2
I
I
I
P
h
n
a
s
e
e
i
t
t
r
e
c
r
u
m
e
e
n
l
d
c
o
s
e		 F
i
l
P
h
I
I
I
n
a
a
s
e
d
t
a
a		 €
A
4
0
i
l
t
l
t
i
p
p
r
o
m
m
e
s
o
n
e
s,
r
o
a
e
s
x.
y
;
€
t
t
i
l
k
t
5
0
0
p
o
e
n
a
m
a
r
e
a
p
p
r
o
m
x.
E
V
T
7
7
0		 T
1
d
2
d
i
b
t
y
p
e
a
n
a
e
e
s
(
b
t
l
l
e
a
c
e
)
t
i
r
e
g
e
n
e
r
a
o
n		 P
l
i
i
l
r
e-
c
n
c
c
a		 N
D		 H
i
h
i
h
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s,
€
2
5
4
i
l
t
/
d
t,
m
m
e
s
o
n
e
s
p
r
o
c
u
f
i
i
i
t
l
t
i
s
g
n
c
a
n
r
o
a
e
s
y
A
L
M		 T
1
d
2
d
i
b
t
p
e
a
n
a
e
e
s
y
(
b
l
l
t
e
a
c
e
i
)
t
r
e
g
e
n
e
r
a
o
n		 P
l
i
i
l
r
e-
c
n
c
c
a		 N
D		 H
i
h
i
h
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
m
e
n
s,
y
€
1
8
3
i
l
/
d
t
t,
m
m
e
s
o
n
e
s
p
r
o
u
c
i
i
f
i
l
i
t
t
s
g
n
c
a
n
r
o
y
a
e
s
E
V
T
0
0
7		 T
T
1
1
d
d
2
2
d
d
i
i
b
b
t
t
y
p
e
a
n
a
e
e
s
(
b
l
l
t
e
a
c
e
t
i
)
r
e
g
e
n
e
r
a
o
n		 P
P
l
l
i
i
i
i
l
r
e-
c
n
c
c
a		 N
D		 H
H
i
i
h
h
i
i
h
h
t
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s,
€
2
3
7
i
l
i
i
f
i
l
i
t
t
t
m
m
e
s
o
n
e
s,
s
g
n
c
a
n
r
o
y
a
e
s
C
B
t
e
a
u
r
e
C
/
B
0
0
2
1
+
h
t
o
e
r
s		 T
1
d
2
d
i
b
t
y
p
e
a
n
a
e
e
s
(
b
t
l
l
e
a
c
e
i
)
t
r
e
g
e
n
e
r
a
o
n		 P
l
i
i
l
c
a
r
e-
c
n
c		 N
D		 H
i
h
i
h
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s
\$
3
0
0
i
l
/
d
i
i
f
i
t
t,
t
m
m
e
s
o
n
e
s
p
r
o
u
c
s
g
n
c
a
n
l
i
t
r
o
y
a
e
s

Novel treatment fomet Phase III endp or T1D points

Product development allia ance with Andromeda/Teva (Phase III)

About DiaPep277®

  • DiaPep277® is a unique peptide of 24 amino acids de erived from human heat shock protein 60 (HSP 60)
  • The peptide acts by modulating the immune system, t that secrete insulin in response to elevated blood gluc thus preventing the destruction of pancreatic cells cose levels

CureBeta – A world without innjectable insulin?

Harvard/Evotec partnersh hip

Betatrophin: A Hormone that Controls Pancreaticβ Cell Proliferation

Authors

Peng Yi, Ji-Sun Park, Douglas A. Melton Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Howard Hughes Medical Institute, Harvard University

Highlights

  • Betatrophin is a secreted protein expressed in liver and fat
  • Betatrophin specifically stimulates pancreatic β cell replication
  • Increase in β cell replication/mass impro es improves glycemic control

Expression of betatrophin1) in mouse liver strongly stimulates beta cell replication

14 1) Betatrophin overexpressing liver cells secrete the protein but not GFP plasmid DNA n into the bloodstream, leading to increased circulating Betatrophin levels in animals injected with Betatrophin

Alzheimer's diseasleading CNS pipel se late-stag pp y e opportunity ine

Neurology pipeline overvi iew

(
)
M
l
l
o
e
c
u
e
s		 I
d
i
t
i
n
c
a
o
n
(
)
h
i
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
t
a
u
s		 N
t
i
l
t
e
x
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
E
V
T
3
0
2		 's
A
l
h
i
e
m
e
r
z
D
i
(
M
A
O
B
)
s
e
a
s
e
-		 P
h
I
I
b
a
s
e		 C
f
l
t
i
P
h
o
m
p
e
o
n
o
a
s
e
I
I,
P
h
I
I
I
t
t
a
s
e
s
a
r		 \$
8
2
0
i
l
t
m
m
e
s
o
n
e
s
i
i
f
i
l
i
t
t
s
g
n
c
a
n
r
o
y
a
e
s
E
V
T
1
0
0
i
s
e
r
e
s		 (
)
D
i
N
R
2
B
e
p
r
e
s
s
o
n		 /
P
h
I
I
a
s
e
l
i
i
l
p
r
e
c
n
c
a		 C
f
f
f
i
t
i
o
n
r
m
a
o
n
o
o
/
l
i
i
l
t
d
p
r
e-
c
n
c
a
s
u
y
P
h
I
/
I
I
t
t
a
s
e
s
a
r		 \$
1
6
0
i
l
t
m
m
e
s
o
n
e
s
f
i
i
i
t
l
t
i
s
g
n
c
a
n
r
o
y
a
e
s
E
V
T
2
0
1		 I
i
n
s
o
m
n
a		 P
h
I
I
a
s
e		 S
l
i
i
l
i
l
t
t
t
a
r
c
n
c
a
r
a
s		 M
M
i
i
l
l
l
i
t
t
t
e
e
s
s
o
o
n
n
e
e
s,
s
r
o
y
a
e
s
V
i
a
r
o
u
s		 H
t
i
t
u
n
n
g
o
n
D
i
s
e
a
s
e		 T
t
l
i
d
t
i
a
r
g
g
e
v
a
a
o
n		 N
A		 R
h
t
e
s
e
a
r
c
p
a
y
m
e
n
s
S
C
f
A
I
i
l
a
m
y		 M
l
t
i
l
l
i
p
e
s
c
e
r
o
s
s
u		 /
B
M
B
F
d
i
l
d
P
h
u
n
s
c
o
s
e
a
r
m
a		 L
d
d
t
i
e
a
g
e
n
e
r
a
o
n		 L
d
t
t
e
a
s
a
s
u		 N
D

Novel treatment off Alzheimer's disease

Product development allia ance with Roche (Phase II)

About RG1577 – EVT302

  • MAO-B is normally present in brain and is responsible e for break-down of certain neurotransmitters
  • Activity of MAO-B is linked to production roduction of reactive eactiveo damage oxygen species, molecules oleculesthat can cause neuronal euronal
  • Blocking the activity of MAO-B should reduce oxidativ ve stress which is expected to slow progression of AD

Uniq yp uel ositione a huge unmet med ed to meet dical need in depression

Product development allia ance with Janssen (Phase I/II)

T
R
D
&
l
i
i
f
N
M
D
A
N
R
2
2
B
b
t
t
t
t
t
s
e
e
c
v
e
a
n
a
g
o
n
s
s
o
r
e
c
e
p
p
o
r
s
u
y
p
e
s
1
)
(
)
T
t
t
i
t
t
d
i
T
R
D
h
i
h
t
d
i
l
d
r
e
a
m
e
n
r
e
s
s
a
n
e
p
r
e
s
s
o
n
a
g
u
n
m
e
e
m
e
c
a
n
e
e

–
1
2
0
S
/
M
t
h
d
d
t
i
t
i
U
E
U
o
r
e
a
n
m
e
p
r
e
s
s
e
p
a
e
n
s
n
–
/
f
f
1
3
t
i
t
d
t
d
t
i
t
l
i
t
i
d
t
o
p
a
e
n
s
o
e
s
n
o
r
e
s
p
o
n
o
r
s
n
e
a
n
e
p
p
r
e
s
s
a
n
–
S
f
f
f
f
i
i
i
t
i
d
t
l
l
i
t
i
i
t
t
i
g
n
c
a
n
s
e
e
e
c
s
o
a
e
x
s
n
g
n
e
r
v
e
n
o
n
s
–
S
f
(
i
i
i
t
d
t
l
t
i
N
M
D
A
t
i
t
k
t
i
g
n
c
a
n
a
a
n
a
g
e
s
o
e
r
n
o
n-
s
e
e
c
e
a
n
a
a
g
o
n
s
s
e
g
e
a
m
n
e
v
v
v

)
f
f
f
d
t
i
d
t
b
t
t
i
d
t
i
l
a
n
m
e
m
a
n
n
e
u
e
o
e
e
r
s
e
e
e
c
p
r
o
e

About NMDA recep yp tor NR2B subtypes

EVT100 are high affinity, selective antagonists of N-met the NR2B subunit; they bind preferentially to the activat mod l t h l ti it b i hibiti h l i dulate channel activity by inhibiting channel opening thyl-D-aspartate (NMDA) receptor subtypes containing ted form of the receptor (activity-dependent); they prob bilit bability

1) Definition CPMP Guidelines: TRD "Consecutive treatm acceptable effect" (Cave pseudo-resistance) ment with 2 products of different classes, used for a sufficient length of time at an adequate dose, fail to induce an

Strong portfolio an novel pain and infl nd p p artnerships for lammation targets

Pain and inflammation pip peline overview

(
)
M
l
l
o
e
c
e
s
u		 I
d
i
t
i
n
c
a
o
n
(
)
h
i
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
s
u		 N
t
i
l
t
e
m
e
s
o
n
e
x		 C
i
l
o
m
m
e
r
c
a
s
E
V
T
4
0
1		 f
I
l
t
i
n
a
m
m
a
o
n
(
2
)
P
X
7
i
h
i
b
i
t
n
o
n		 /
P
h
I
I
I
a
s
e		 P
h
I
I
t
t
a
s
e
s
a
r		 €
6
0
i
l
t
l
t
i
a
p
p
r
o
m
m
e
s
o
n
e
s,
r
o
a
e
s
x.
y
V
i
a
r
o
u
s		 E
d
i
i
t
n
o
m
e
r
o
s
s		 P
l
i
i
l
r
e-
c
n
c
a		 P
l
i
i
l
r
e-
c
n
c
a
d
i
d
t
c
a
n
a
e		 f
€
1
2
U
t
t
t
l
l
t
p
r
o
n
m
o
a
v
a
u
e
u
p
o
a
p
p
r
o
x.
,
€
8
0
5
l
t
i
m
;
r
o
y
a
e
s
V
i
a
r
o
s
u		 V
i
/
P
i
a
r
o
s
a
n
u		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
I
t
t
a
s
e
s
a
r		 R
h
t
i
l
t
l
t
i
e
s
e
a
r
c
p
a
m
e
n
s,
m
e
s
o
n
e
s,
r
o
a
e
s
y
y
V
i
a
r
o
u
s		 f
f
I
I
l
l
t
t
i
i
n
a
m
m
a
o
n		 P
l
i
i
l
r
e-
c
n
c
a		 P
P
h
h
I
I
t
t
t
t
a
s
e
s
a
r		 H
H
i
i
h
h
i
i
h
h
t
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s,
€
1
8
3
i
l
/
d
t
t,
m
m
e
s
o
n
e
s
p
r
o
u
c
i
i
f
i
l
i
t
t
s
g
n
c
a
n
r
o
y
a
e
s
U
d
i
l
d
n
s
c
o
s
e		 V
i
/
P
i
a
r
o
u
s
a
n		 P
l
i
i
l
r
e-
c
n
c
a		 S
f
l
P
C
u
c
c
e
s
s
u
o		 R
h
i
i
l
l
l
i
t
t
t
t
t
e
s
e
a
r
c
p
p
a
a
y
y
m
m
e
e
n
n
s,
s
m
m
e
e
s
s
o
o
n
n
e
e
s
s,
r
o
y
a
e
s

BI alliance leads p pipeline of oncology targets

Oncology pipeline overvie w

(
)
M
l
l
o
e
c
e
s
u		 I
d
i
t
i
n
c
a
o
n
(
)
h
i
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
s
u		 N
t
i
l
t
e
m
e
s
o
n
e
x		 C
i
l
o
m
m
e
r
c
a
s
D
G
3
1
7
3		 A
l
/
N
E
T
c
r
o
m
e
g
a
y		 P
h
I
I
a
s
e
a		 P
h
I
I
d
t
i
a
s
e
a
a
n
l
a
c
r
o
m
e
g
a
y		 C
l
t
i
f
l
t
i
o
n
s
n
g
e
e
s,
r
o
a
e
s
u
y
V
i
a
r
o
u
s		 V
i
a
r
o
u
s		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
I,
F
i
i
t
a
s
e
r
s
n
m
a
n		 R
h
i
l
t
t
e
s
e
a
r
c
p
a
y
m
e
n
s,
m
e
s
o
n
e
s,
l
i
t
r
o
y
a
e
s
P
h
t
a
w
a
y
s
c
r
e
e
n		 C
b
l-
B
h
t
p
a
w
a
y		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
h
i
t
a
r
m
a
p
a
r
n
e
r
s
p		 S
h
d
h
t
a
r
e
r
e
s
e
a
r
c
c
o
s
s,
i
l
t
l
t
i
m
e
s
o
n
e
s,
r
o
a
e
s
y
E
i
i
i
p
g
e
n
o
m
c
s
t
t
a
r
g
e
s		 V
V
i
i
a
r
o
s
u		 P
P
l
l
i
i
i
i
l
l
r
e-
c
n
c
a		 P
h
t
h
i
a
r
m
a
p
a
r
n
e
r
s
p		 N
A
GE
PA
19

Harvard & Yale as and Target X strate partners for Cure X egy

Cure X/Target X overview w

O
i
i
t
p
e
n
n
n
o
a
o
n
v
i
t
h
Y
l
w
a
e		 C
l
l
b
t
i
t
i
d
t
i
f
d
i
l
i
d
i
o
a
o
r
a
o
n
o
e
n
a
n
n
c
o
m
m
e
r
c
a
s
e
s
c
o
e
r
y
v
y

t
i
t
i
i
t
i
Y
l
i
o
p
p
o
r
n
e
s
a
s
o
p
e
n
n
n
o
o
a
o
n
p
r
o
c
e
s
s
a
c
r
o
s
s
a
e
s
c
e
n
c
e
u
v		 Y
C
N
h
r
e
e
p
r
o
n
u
i
h
H
d
t
a
r
a
r
w
v		 f
f
f
f
f
P
t
l
i
h
t
i
d
t
i
d
d
i
i
d
d
i
i
i
i
h
i
o
r
o
o
o
a
p
p
r
o
a
c
e
s
o
e
n
s
s
e
e
a
a
s
s
e
e
-m
m
o
o
n
n
g
g
m
e
c
a
n
s
m
s
y
y
y

H
i
h
l
d
i
i
t
t
i
d
i
d
t
t
t
g
y
p
r
o
u
c
v
e
n
g
e
n
e
r
r
a
n
g
c
a
n
a
e
a
r
g
e
s
/
C
X
T
X
t
r
e
a
r
g
e
u		 C
f
l
i
l
d
l
j
t
t
t
t
o
n
c
e
p
o
r
s
e
v
e
r
a
n
e
r
n
a
a
n
e
x
e
r
n
a
p
r
o
e
c
s

E
E
i
i
i
h
B
B
l
l
f
f
l
l
f
i
b
i
l
t
t
t
t
t
t
t
g
g
e
p
g
e
n
e
c
a
r
g
e
s
w
e
e
e
e
r,
r
n
e
w
c
c
a
a
s
s
s
s
o
a
n
a
c
e
r
a
s

(
H
d
)
a
r
a
r
v		 X

First-in-class prod even stronger port duct candidates and an tfolio of partnerships

EVT Innovate/Integrate st trategy

PAGE21

Agenda

  • Evotec at a glance
  • Driving Innovation Efficie ency
  • Financial strategy & O utlook

Focused R&D inveestments accelerate strategy

Key financials Q1: Conden nsed income statement (IFRS)

i
€
n
m
Q
1
2
0
1
1
2		 Q
1
2
0
1
3
A
t
l
c
u
a
R
e
e
n
e
s
v
u		 2
0
1		 1
7
1
G
i
r
o
s
s
m
a
r
g
n		 %
%
3
2
5		 %
2
6
1
&
R
D
e
x
p
e
n
s
e
s
 1
9		 2
3
S
G
&
A
e
p
e
n
s
e
s
x
 4
4		 3
9
A
i
i
t
t
m
o
r
s
a
o
n
 0
5		 0
9
O
t
h
t
i
t
e
r
o
p
e
r
a
n
g
e
x
p
e
n
s
e
s
n
e

,		 1
)
0
9		 0
0
O
i
i
(
l
)
t
p
e
r
a
n
g
n
c
o
m
e
o
s
s		 (
1
3
)		 (
(
2
2
)
)
7
7
N
i
(
l
)
t
e
n
c
o
m
e
o
s
s		 (
2
0
)		 (
2
9
)

Excluding milestones, revenues would have increased by 5% and operating loss would have improved compared to the prior year period

23 1) Including fair value adjustment in the context of the con planned under utilisation of € 0.6 m ntingent consideration (earn-out DeveloGen) of € 0.3 m and parallel rental in Hamburg and the resulting

Accelerated innovvation strategy

Key metrics for 2013

in € m

The right team to deliver innovation, growth and industrialisation

Management & shareholder structure

Strong news flow to come

Outlook and next steps for r 2013 ff

Key milestones for 2013

R
t
h
d
i
e
v
e
n
u
e
g
r
o
w
a
n
n
c
E
V
T
E
t
1
x
e
c
u
e		 f
E
i
p
a
n
s
o
n
s
c
c
e
s
s
o
e
x
u
x
S
i
i
f
i
l
d
t
t
g
n
c
a
n
o
n
g
e
r
m
e
a

-

At least 1 significant new Accelerated pre-clinical/ 2 EVT Integrate w integrated technology/disease alliance /clinical milestones

creasing gross margin

als with big and mid-sized Pharma and Biotech

xisting alliances

  • Strong progress in produ uct development partnerships
  • Expansion of network of f academic alliances
  • Partnering of one pre-cli nical asset/development programme

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
AGM Information 2026
May 7
Interim / Quarterly Report 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Major Shareholding Notification 2026
May 5
View all filings →